

*A2*  
*Concl'd.*

sequence selected from the group consisting of SEQ. ID No. 4 and SEQ. ID No. 6 in a physiologically acceptable carrier or diluent.

4. (Amended) The pharmaceutical composition [as set forth in claim 1] of a synthetic nuclease resistant antisense oligodeoxynucleotide comprising either SEQ. ID No. 4 or SEQ. ID No. 6 and at least one other non-control AS-ODN selected from Tables 1 and 2 wherein a percent inhibition is greater than 25%.

Claim 5, line 2, please delete "capable of" and insert therefor  
-for--.

*A*  
*B*

7. (Amended) A pharmaceutical composition for selectively [modulating] inhibiting mammalian [tumor] tumor necrosis factor alpha in a mammal in need of such treatment consisting of

*Sub C2*

an effective amount of at least one active ingredient [as set forth in claim 1] of a synthetic nuclease resistant antisense oligodeoxynucleotide having a nucleotide sequence selected from the group consisting of SEQ. ID No. 4 and SEQ. ID No. 6 in a pharmaceutically physiologically acceptable carrier or diluent.

*A4*  
*Cont'd.*  
*B*

13. (New) A method of selectively regulating mammalian tumor necrosis factor alpha by the steps of targeting for treatment the tumor necrosis factor alpha splice region and then specifically modify the region to inhibit the mammalian tumor necrosis factor alpha.

*Sub C3*

14. (New) The method of claim 13 further including the step of administering an effective amount of a synthetic nuclease resistant antisense oligodeoxynucleotide which targets exon sequences flanking donor splice sites.

15. (New) A method of inhibiting tumor necrosis factor alpha by targeting for treatment the tumor necrosis factor alpha splice region.